Date: 2016-12-15
Type of information: Company acquisition
Acquired company: TangenX Technology (USA - MA)
Acquiring company: Repligen (USA - MA)
Amount: €37 million ($ 39 million)
Terms: * On December 15, 2016, Novasep, a leading supplier of manufacturing solutions for the life science industries, announced the sale of its U.S. subsidiary, TangenX Technology Corporation (TangenX), to Repligen Corporation. The all-cash transaction of €37 million ($ 39 million) was completed today. Fox Rothschild LLP (Philadelphia, PA, USA) served as legal counsel to Novasep in the deal, and Brocair Partners (New York, NY, USA) provided financial advisory services. In 2006, Novasep acquired a majority stake in TangenX, located in Shrewsbury, Massachusetts, USA. The company develops, produces and sells tangential flow filtration (TFF) technologies that enable biomanufacturers to significantly reduce industrial purification costs of biopharmaceuticals. Its innovative single-use TFF cassettes Sius™ currently command strong sales.
Details:
Related: Technology - Services
